nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—Disease progression—Sorafenib—liver cancer	0.0205	0.0744	CcSEcCtD
Carfilzomib—Peripheral sensory neuropathy—Sorafenib—liver cancer	0.0157	0.0568	CcSEcCtD
Carfilzomib—Peripheral motor neuropathy—Epirubicin—liver cancer	0.00906	0.0329	CcSEcCtD
Carfilzomib—Lymphopenia—Sorafenib—liver cancer	0.00875	0.0317	CcSEcCtD
Carfilzomib—Peripheral motor neuropathy—Doxorubicin—liver cancer	0.00838	0.0304	CcSEcCtD
Carfilzomib—Hypophosphataemia—Sorafenib—liver cancer	0.0077	0.0279	CcSEcCtD
Carfilzomib—Tumour lysis syndrome—Epirubicin—liver cancer	0.00596	0.0216	CcSEcCtD
Carfilzomib—Peripheral sensory neuropathy—Epirubicin—liver cancer	0.00579	0.021	CcSEcCtD
Carfilzomib—Myocardial ischaemia—Sorafenib—liver cancer	0.00557	0.0202	CcSEcCtD
Carfilzomib—Tumour lysis syndrome—Doxorubicin—liver cancer	0.00552	0.02	CcSEcCtD
Carfilzomib—Peripheral sensory neuropathy—Doxorubicin—liver cancer	0.00536	0.0194	CcSEcCtD
Carfilzomib—Multi-organ failure—Epirubicin—liver cancer	0.00508	0.0184	CcSEcCtD
Carfilzomib—Multi-organ failure—Doxorubicin—liver cancer	0.0047	0.017	CcSEcCtD
Carfilzomib—Musculoskeletal chest pain—Epirubicin—liver cancer	0.00427	0.0155	CcSEcCtD
Carfilzomib—Musculoskeletal chest pain—Doxorubicin—liver cancer	0.00395	0.0143	CcSEcCtD
Carfilzomib—Hepatic failure—Sorafenib—liver cancer	0.00362	0.0131	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Sorafenib—liver cancer	0.00358	0.013	CcSEcCtD
Carfilzomib—Renal failure acute—Sorafenib—liver cancer	0.00352	0.0128	CcSEcCtD
Carfilzomib—Hyponatraemia—Sorafenib—liver cancer	0.00326	0.0118	CcSEcCtD
Carfilzomib—Pain in extremity—Sorafenib—liver cancer	0.00325	0.0118	CcSEcCtD
Carfilzomib—Lymphopenia—Epirubicin—liver cancer	0.00323	0.0117	CcSEcCtD
Carfilzomib—Lymphopenia—Doxorubicin—liver cancer	0.00299	0.0109	CcSEcCtD
Carfilzomib—Hypokalaemia—Sorafenib—liver cancer	0.00296	0.0107	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00293	0.0106	CcSEcCtD
Carfilzomib—Hypophosphataemia—Epirubicin—liver cancer	0.00285	0.0103	CcSEcCtD
Carfilzomib—Hypophosphataemia—Doxorubicin—liver cancer	0.00263	0.00955	CcSEcCtD
Carfilzomib—Neutropenia—Sorafenib—liver cancer	0.00263	0.00953	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Epirubicin—liver cancer	0.0026	0.00945	CcSEcCtD
Carfilzomib—Pneumonia—Sorafenib—liver cancer	0.00252	0.00914	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Sorafenib—liver cancer	0.00247	0.00896	CcSEcCtD
Carfilzomib—Renal failure—Sorafenib—liver cancer	0.00246	0.00893	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Sorafenib—liver cancer	0.00245	0.0089	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Doxorubicin—liver cancer	0.00241	0.00874	CcSEcCtD
Carfilzomib—Hypercalcaemia—Epirubicin—liver cancer	0.00238	0.00864	CcSEcCtD
Carfilzomib—Neuritis—Epirubicin—liver cancer	0.00222	0.00804	CcSEcCtD
Carfilzomib—Hypercalcaemia—Doxorubicin—liver cancer	0.0022	0.00799	CcSEcCtD
Carfilzomib—Cardiac disorder—Sorafenib—liver cancer	0.00209	0.00757	CcSEcCtD
Carfilzomib—Neuritis—Doxorubicin—liver cancer	0.00205	0.00744	CcSEcCtD
Carfilzomib—Muscle spasms—Sorafenib—liver cancer	0.00188	0.00683	CcSEcCtD
Carfilzomib—Anaemia—Sorafenib—liver cancer	0.00181	0.00656	CcSEcCtD
Carfilzomib—Leukopenia—Sorafenib—liver cancer	0.00175	0.00635	CcSEcCtD
Carfilzomib—PSMB1—embryo—liver cancer	0.00173	0.194	CbGeAlD
Carfilzomib—Cough—Sorafenib—liver cancer	0.00171	0.00619	CcSEcCtD
Carfilzomib—Hypertension—Sorafenib—liver cancer	0.00169	0.00613	CcSEcCtD
Carfilzomib—PSMB2—embryo—liver cancer	0.00169	0.189	CbGeAlD
Carfilzomib—Arthralgia—Sorafenib—liver cancer	0.00167	0.00604	CcSEcCtD
Carfilzomib—PSMB10—liver—liver cancer	0.00161	0.18	CbGeAlD
Carfilzomib—Infection—Sorafenib—liver cancer	0.00159	0.00576	CcSEcCtD
Carfilzomib—Thrombocytopenia—Sorafenib—liver cancer	0.00156	0.00567	CcSEcCtD
Carfilzomib—Anorexia—Sorafenib—liver cancer	0.00152	0.00552	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00146	0.00528	CcSEcCtD
Carfilzomib—Sepsis—Epirubicin—liver cancer	0.00144	0.00521	CcSEcCtD
Carfilzomib—Dyspnoea—Sorafenib—liver cancer	0.00142	0.00517	CcSEcCtD
Carfilzomib—Decreased appetite—Sorafenib—liver cancer	0.00139	0.00504	CcSEcCtD
Carfilzomib—Fatigue—Sorafenib—liver cancer	0.00138	0.005	CcSEcCtD
Carfilzomib—Ritonavir—CYP2E1—liver cancer	0.00137	1	CrCbGaD
Carfilzomib—Constipation—Sorafenib—liver cancer	0.00137	0.00495	CcSEcCtD
Carfilzomib—Pain—Sorafenib—liver cancer	0.00137	0.00495	CcSEcCtD
Carfilzomib—Hepatic failure—Epirubicin—liver cancer	0.00134	0.00485	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—liver cancer	0.00133	0.00482	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Epirubicin—liver cancer	0.00132	0.0048	CcSEcCtD
Carfilzomib—Renal failure acute—Epirubicin—liver cancer	0.0013	0.00472	CcSEcCtD
Carfilzomib—Body temperature increased—Sorafenib—liver cancer	0.00126	0.00458	CcSEcCtD
Carfilzomib—Hepatic failure—Doxorubicin—liver cancer	0.00124	0.00449	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Doxorubicin—liver cancer	0.00123	0.00444	CcSEcCtD
Carfilzomib—Hyponatraemia—Epirubicin—liver cancer	0.00121	0.00437	CcSEcCtD
Carfilzomib—Renal failure acute—Doxorubicin—liver cancer	0.0012	0.00437	CcSEcCtD
Carfilzomib—Pain in extremity—Epirubicin—liver cancer	0.0012	0.00436	CcSEcCtD
Carfilzomib—Asthenia—Sorafenib—liver cancer	0.00115	0.00416	CcSEcCtD
Carfilzomib—Cardiac arrest—Epirubicin—liver cancer	0.00114	0.00414	CcSEcCtD
Carfilzomib—Blood creatinine increased—Epirubicin—liver cancer	0.00113	0.00408	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—liver cancer	0.00112	0.00405	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—liver cancer	0.00111	0.00403	CcSEcCtD
Carfilzomib—Hypokalaemia—Epirubicin—liver cancer	0.00109	0.00396	CcSEcCtD
Carfilzomib—Diarrhoea—Sorafenib—liver cancer	0.00109	0.00396	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00108	0.00392	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—liver cancer	0.00106	0.00383	CcSEcCtD
Carfilzomib—Dizziness—Sorafenib—liver cancer	0.00106	0.00383	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—liver cancer	0.00104	0.00378	CcSEcCtD
Carfilzomib—PSMB8—liver—liver cancer	0.00104	0.116	CbGeAlD
Carfilzomib—Vomiting—Sorafenib—liver cancer	0.00102	0.00368	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—liver cancer	0.00101	0.00367	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.001	0.00363	CcSEcCtD
Carfilzomib—Headache—Sorafenib—liver cancer	0.001	0.00363	CcSEcCtD
Carfilzomib—Neutropenia—Epirubicin—liver cancer	0.000971	0.00352	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—liver cancer	0.000965	0.0035	CcSEcCtD
Carfilzomib—Nausea—Sorafenib—liver cancer	0.000949	0.00344	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—liver cancer	0.000936	0.0034	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—liver cancer	0.000931	0.00338	CcSEcCtD
Carfilzomib—PSMB5—liver—liver cancer	0.000915	0.102	CbGeAlD
Carfilzomib—Renal failure—Epirubicin—liver cancer	0.00091	0.0033	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—liver cancer	0.000907	0.00329	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—liver cancer	0.000898	0.00326	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000893	0.00324	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—liver cancer	0.000866	0.00314	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—liver cancer	0.000861	0.00312	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—liver cancer	0.000842	0.00305	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—liver cancer	0.000839	0.00304	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—liver cancer	0.000827	0.003	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—liver cancer	0.000819	0.00297	CcSEcCtD
Carfilzomib—PSMB1—liver—liver cancer	0.0008	0.0895	CbGeAlD
Carfilzomib—PSMB2—liver—liver cancer	0.00078	0.0874	CbGeAlD
Carfilzomib—Cardiac disorder—Epirubicin—liver cancer	0.000771	0.0028	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—liver cancer	0.000765	0.00277	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—liver cancer	0.000757	0.00275	CcSEcCtD
Carfilzomib—Chills—Epirubicin—liver cancer	0.000746	0.0027	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—liver cancer	0.000713	0.00259	CcSEcCtD
Carfilzomib—Back pain—Epirubicin—liver cancer	0.0007	0.00254	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—liver cancer	0.000695	0.00252	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—liver cancer	0.00069	0.0025	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—liver cancer	0.000669	0.00242	CcSEcCtD
Carfilzomib—Leukopenia—Epirubicin—liver cancer	0.000647	0.00235	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—liver cancer	0.000647	0.00235	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—liver cancer	0.000643	0.00233	CcSEcCtD
Carfilzomib—Cough—Epirubicin—liver cancer	0.000631	0.00229	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—liver cancer	0.000624	0.00227	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—liver cancer	0.000619	0.00224	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—liver cancer	0.000616	0.00223	CcSEcCtD
Carfilzomib—Leukopenia—Doxorubicin—liver cancer	0.000599	0.00217	CcSEcCtD
Carfilzomib—Infection—Epirubicin—liver cancer	0.000586	0.00213	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—liver cancer	0.000584	0.00212	CcSEcCtD
Carfilzomib—Thrombocytopenia—Epirubicin—liver cancer	0.000578	0.0021	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—liver cancer	0.000578	0.0021	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—liver cancer	0.00057	0.00207	CcSEcCtD
Carfilzomib—Anorexia—Epirubicin—liver cancer	0.000563	0.00204	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—liver cancer	0.000543	0.00197	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000538	0.00195	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—liver cancer	0.000535	0.00194	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—liver cancer	0.000534	0.00194	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—liver cancer	0.000526	0.00191	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—liver cancer	0.000521	0.00189	CcSEcCtD
Carfilzomib—Decreased appetite—Epirubicin—liver cancer	0.000513	0.00186	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—liver cancer	0.000509	0.00185	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—liver cancer	0.000505	0.00183	CcSEcCtD
Carfilzomib—Pain—Epirubicin—liver cancer	0.000505	0.00183	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000498	0.00181	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—liver cancer	0.000494	0.00179	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—liver cancer	0.000487	0.00177	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—liver cancer	0.000475	0.00172	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—liver cancer	0.000471	0.00171	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—liver cancer	0.000467	0.00169	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—liver cancer	0.000467	0.00169	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—liver cancer	0.000467	0.00169	CcSEcCtD
Carfilzomib—Body temperature increased—Doxorubicin—liver cancer	0.000432	0.00157	CcSEcCtD
Carfilzomib—Asthenia—Epirubicin—liver cancer	0.000424	0.00154	CcSEcCtD
Carfilzomib—Diarrhoea—Epirubicin—liver cancer	0.000404	0.00147	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—liver cancer	0.000392	0.00142	CcSEcCtD
Carfilzomib—Dizziness—Epirubicin—liver cancer	0.00039	0.00142	CcSEcCtD
Carfilzomib—Vomiting—Epirubicin—liver cancer	0.000375	0.00136	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—liver cancer	0.000374	0.00136	CcSEcCtD
Carfilzomib—Headache—Epirubicin—liver cancer	0.00037	0.00134	CcSEcCtD
Carfilzomib—Dizziness—Doxorubicin—liver cancer	0.000361	0.00131	CcSEcCtD
Carfilzomib—Nausea—Epirubicin—liver cancer	0.000351	0.00127	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—liver cancer	0.000347	0.00126	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—liver cancer	0.000342	0.00124	CcSEcCtD
Carfilzomib—Nausea—Doxorubicin—liver cancer	0.000324	0.00118	CcSEcCtD
Carfilzomib—ABCB1—embryo—liver cancer	0.000258	0.0289	CbGeAlD
Carfilzomib—ABCB1—liver—liver cancer	0.000119	0.0133	CbGeAlD
Carfilzomib—PSMB2—Metabolism—PIK3CB—liver cancer	1.83e-05	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—STAT3—liver cancer	1.83e-05	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—STAT3—liver cancer	1.83e-05	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—STAT3—liver cancer	1.83e-05	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCND1—liver cancer	1.81e-05	2.54e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CB—liver cancer	1.81e-05	2.53e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—JUN—liver cancer	1.81e-05	2.53e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—STAT3—liver cancer	1.81e-05	2.53e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCND1—liver cancer	1.8e-05	2.52e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—JUN—liver cancer	1.8e-05	2.52e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CTNNB1—liver cancer	1.79e-05	2.51e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CTNNB1—liver cancer	1.78e-05	2.5e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	1.77e-05	2.48e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HRAS—liver cancer	1.76e-05	2.47e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—PIK3CA—liver cancer	1.76e-05	2.47e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CD—liver cancer	1.76e-05	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CD—liver cancer	1.76e-05	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CD—liver cancer	1.76e-05	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MMP9—liver cancer	1.76e-05	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HRAS—liver cancer	1.76e-05	2.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CRABP1—liver cancer	1.76e-05	2.46e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	1.75e-05	2.46e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—PIK3CA—liver cancer	1.75e-05	2.45e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CDKN1A—liver cancer	1.75e-05	2.45e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MMP9—liver cancer	1.75e-05	2.45e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CDKN1A—liver cancer	1.74e-05	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SERPINE1—liver cancer	1.74e-05	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SERPINE1—liver cancer	1.74e-05	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SERPINE1—liver cancer	1.74e-05	2.44e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CD—liver cancer	1.73e-05	2.43e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SERPINE1—liver cancer	1.71e-05	2.4e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	1.71e-05	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK8—liver cancer	1.71e-05	2.39e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK8—liver cancer	1.7e-05	2.38e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MYC—liver cancer	1.69e-05	2.37e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MYC—liver cancer	1.69e-05	2.37e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MYC—liver cancer	1.69e-05	2.37e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—STAT3—liver cancer	1.69e-05	2.37e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—STAT3—liver cancer	1.69e-05	2.37e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—STAT3—liver cancer	1.69e-05	2.37e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6—liver cancer	1.69e-05	2.36e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6—liver cancer	1.68e-05	2.35e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—liver cancer	1.67e-05	2.34e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—STAT3—liver cancer	1.67e-05	2.34e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—liver cancer	1.63e-05	2.28e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—liver cancer	1.62e-05	2.27e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—liver cancer	1.58e-05	2.21e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—RAF1—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—RAF1—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—RAF1—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TGFB1—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TGFB1—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TGFB1—liver cancer	1.57e-05	2.2e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—liver cancer	1.56e-05	2.19e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—liver cancer	1.56e-05	2.18e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—liver cancer	1.56e-05	2.18e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—liver cancer	1.56e-05	2.18e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—liver cancer	1.55e-05	2.17e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—liver cancer	1.55e-05	2.17e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—liver cancer	1.55e-05	2.17e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—liver cancer	1.55e-05	2.17e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—liver cancer	1.55e-05	2.17e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—RAF1—liver cancer	1.55e-05	2.17e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TGFB1—liver cancer	1.55e-05	2.16e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—liver cancer	1.54e-05	2.16e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HPGDS—liver cancer	1.53e-05	2.15e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CB—liver cancer	1.53e-05	2.15e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CB—liver cancer	1.53e-05	2.15e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MTOR—liver cancer	1.53e-05	2.15e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MTOR—liver cancer	1.53e-05	2.15e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MTOR—liver cancer	1.53e-05	2.15e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CB—liver cancer	1.53e-05	2.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MTOR—liver cancer	1.51e-05	2.12e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CB—liver cancer	1.51e-05	2.12e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—liver cancer	1.47e-05	2.06e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—liver cancer	1.47e-05	2.05e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—liver cancer	1.45e-05	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—liver cancer	1.45e-05	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—liver cancer	1.45e-05	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—liver cancer	1.45e-05	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TGFB1—liver cancer	1.45e-05	2.03e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—liver cancer	1.45e-05	2.02e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—liver cancer	1.45e-05	2.02e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—liver cancer	1.45e-05	2.02e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—liver cancer	1.45e-05	2.02e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	1.44e-05	2.02e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TGFB1—liver cancer	1.44e-05	2.02e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1B—liver cancer	1.44e-05	2.01e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1B—liver cancer	1.44e-05	2.01e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1B—liver cancer	1.44e-05	2.01e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—liver cancer	1.44e-05	2.01e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—liver cancer	1.43e-05	2.01e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—liver cancer	1.43e-05	2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—liver cancer	1.42e-05	2e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1B—liver cancer	1.42e-05	1.99e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CASP3—liver cancer	1.41e-05	1.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CASP3—liver cancer	1.41e-05	1.97e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CASP3—liver cancer	1.41e-05	1.97e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—liver cancer	1.41e-05	1.97e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—liver cancer	1.41e-05	1.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—liver cancer	1.41e-05	1.97e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CASP3—liver cancer	1.39e-05	1.95e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—liver cancer	1.39e-05	1.94e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—liver cancer	1.37e-05	1.92e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—liver cancer	1.37e-05	1.92e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—liver cancer	1.37e-05	1.92e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—JUN—liver cancer	1.37e-05	1.92e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—JUN—liver cancer	1.37e-05	1.92e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—JUN—liver cancer	1.37e-05	1.92e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PSMA4—liver cancer	1.37e-05	1.91e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PSMD10—liver cancer	1.37e-05	1.91e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CTNNB1—liver cancer	1.36e-05	1.9e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CTNNB1—liver cancer	1.36e-05	1.9e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CTNNB1—liver cancer	1.36e-05	1.9e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—liver cancer	1.35e-05	1.89e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—JUN—liver cancer	1.35e-05	1.89e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—liver cancer	1.34e-05	1.88e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CTNNB1—liver cancer	1.34e-05	1.88e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—liver cancer	1.34e-05	1.87e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—liver cancer	1.34e-05	1.87e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—liver cancer	1.34e-05	1.87e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—liver cancer	1.34e-05	1.87e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—liver cancer	1.33e-05	1.87e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—liver cancer	1.33e-05	1.87e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—liver cancer	1.33e-05	1.87e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—liver cancer	1.33e-05	1.87e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—liver cancer	1.33e-05	1.87e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—liver cancer	1.33e-05	1.87e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GOT2—liver cancer	1.33e-05	1.86e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1A—liver cancer	1.33e-05	1.86e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1A—liver cancer	1.33e-05	1.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1A—liver cancer	1.33e-05	1.86e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—liver cancer	1.32e-05	1.85e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—liver cancer	1.32e-05	1.84e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—liver cancer	1.31e-05	1.84e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1A—liver cancer	1.31e-05	1.83e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	1.3e-05	1.83e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK8—liver cancer	1.3e-05	1.81e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK8—liver cancer	1.3e-05	1.81e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK8—liver cancer	1.3e-05	1.81e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—liver cancer	1.28e-05	1.79e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—liver cancer	1.28e-05	1.79e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—liver cancer	1.28e-05	1.79e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK8—liver cancer	1.28e-05	1.79e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—liver cancer	1.26e-05	1.77e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP2E1—liver cancer	1.25e-05	1.75e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—liver cancer	1.23e-05	1.73e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—liver cancer	1.23e-05	1.73e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—liver cancer	1.23e-05	1.73e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—liver cancer	1.23e-05	1.73e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—liver cancer	1.23e-05	1.72e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—liver cancer	1.22e-05	1.7e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—liver cancer	1.2e-05	1.69e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—liver cancer	1.2e-05	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—liver cancer	1.2e-05	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—liver cancer	1.2e-05	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—liver cancer	1.2e-05	1.68e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—liver cancer	1.19e-05	1.67e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—liver cancer	1.19e-05	1.66e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—liver cancer	1.18e-05	1.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—liver cancer	1.18e-05	1.66e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—liver cancer	1.18e-05	1.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—liver cancer	1.18e-05	1.65e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—liver cancer	1.18e-05	1.65e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—liver cancer	1.18e-05	1.65e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—liver cancer	1.18e-05	1.65e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—liver cancer	1.18e-05	1.65e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—liver cancer	1.18e-05	1.65e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—liver cancer	1.18e-05	1.65e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	1.18e-05	1.65e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—liver cancer	1.17e-05	1.64e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—liver cancer	1.17e-05	1.64e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—liver cancer	1.17e-05	1.64e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYCS—liver cancer	1.17e-05	1.64e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—liver cancer	1.17e-05	1.64e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—liver cancer	1.16e-05	1.63e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—liver cancer	1.16e-05	1.63e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—liver cancer	1.16e-05	1.62e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GGT1—liver cancer	1.15e-05	1.61e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GOT1—liver cancer	1.15e-05	1.61e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—liver cancer	1.14e-05	1.6e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—liver cancer	1.14e-05	1.59e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—liver cancer	1.12e-05	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—liver cancer	1.12e-05	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—liver cancer	1.12e-05	1.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—liver cancer	1.1e-05	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—liver cancer	1.1e-05	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—liver cancer	1.1e-05	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—liver cancer	1.1e-05	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TGFB1—liver cancer	1.1e-05	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TGFB1—liver cancer	1.1e-05	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TGFB1—liver cancer	1.1e-05	1.54e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—liver cancer	1.09e-05	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—liver cancer	1.09e-05	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—liver cancer	1.09e-05	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—liver cancer	1.09e-05	1.53e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—liver cancer	1.09e-05	1.52e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—liver cancer	1.09e-05	1.52e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TGFB1—liver cancer	1.08e-05	1.52e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—liver cancer	1.07e-05	1.5e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTP1—liver cancer	1.03e-05	1.44e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—HMOX1—liver cancer	1.02e-05	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—liver cancer	1.02e-05	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—liver cancer	1.02e-05	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—liver cancer	1.02e-05	1.42e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—liver cancer	1.01e-05	1.41e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—liver cancer	1e-05	1.4e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—liver cancer	1e-05	1.4e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—GSTM1—liver cancer	9.48e-06	1.33e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—liver cancer	9.34e-06	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—liver cancer	9.34e-06	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—liver cancer	9.34e-06	1.31e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—liver cancer	9.21e-06	1.29e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—liver cancer	9.13e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—liver cancer	9.13e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—liver cancer	9.13e-06	1.28e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—liver cancer	9.04e-06	1.27e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—liver cancer	9.04e-06	1.27e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—liver cancer	9.04e-06	1.27e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—liver cancer	9e-06	1.26e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP1A1—liver cancer	8.98e-06	1.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—liver cancer	8.91e-06	1.25e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—liver cancer	8.64e-06	1.21e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—liver cancer	8.64e-06	1.21e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—liver cancer	8.64e-06	1.21e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—liver cancer	8.52e-06	1.19e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—MTHFR—liver cancer	8.38e-06	1.17e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—liver cancer	8.27e-06	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—liver cancer	8.27e-06	1.16e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—liver cancer	8.27e-06	1.16e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARA—liver cancer	8.22e-06	1.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—liver cancer	8.16e-06	1.14e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—liver cancer	7.63e-06	1.07e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—liver cancer	7.63e-06	1.07e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—liver cancer	7.63e-06	1.07e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—liver cancer	7.52e-06	1.05e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CG—liver cancer	7.04e-06	9.86e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARG—liver cancer	6.79e-06	9.51e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CD—liver cancer	6.19e-06	8.66e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ALB—liver cancer	6.11e-06	8.55e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CB—liver cancer	5.39e-06	7.55e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—liver cancer	3.29e-06	4.6e-06	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—liver cancer	2.69e-06	3.76e-06	CbGpPWpGaD
